Holen Sie sich die Stockscreener-App
35.47
11.23%
3.58
Handel nachbörslich:
35.25
-0.22
-0.62%
Schlusskurs vom Vortag:
$31.89
Offen:
$32.6
24-Stunden-Volumen:
31.77M
Relative Volume:
1.21
Marktkapitalisierung:
$8.21B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
67.94
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+22.86%
1M Leistung:
+59.13%
6M Leistung:
+2.01%
1J Leistung:
-41.92%
1-Tages-Spanne:
$32.59
$35.60
1-Wochen-Bereich:
$26.52
$35.60
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
35.47 | 8.21B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
HIMS Stock Logs Best Day In 2 Months: Bull Sees Peptides Driving Up To $19B In Annual Revenue By 2030 - Stocktwits
Hims & Hers Health Inc (HIMS) Shares Surge 11.2% -- What GF Scor - GuruFocus
HIMS Shows Strong Bullish Momentum with Notable Stock Surge - GuruFocus
HIMS (NYSE) Form 144: 12,500 and 11,226 vested Class A shares listed - Stock Titan
Hims & Hers Stock Jumps After Barclays Raises Price Target - Benzinga
Hims & Hers Rallies With a July FDA Decision Looming - TradingView
HIMS Maintained by Barclays -- Price Target Raised to $39.00 - GuruFocus
Hims & Hers Health gains as investors appear to lean into growth outlook and global expansion - Quiver Quantitative
Closed all position, was too greedy aiming for highest 34.65 ended up earned a bit lesser - Moomoo
Why is Hims & Hers Health stock surging today? - Investing.com
Hims & Hers: The Bull Case Remains Strong (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health: Legal Risks Resolved With New International Growth Driver (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health, Inc. (HIMS) ascends while market falls: Some facts to note - MSN
Hims & Hers COO Michael Chi sells $441,850 in company stock By Investing.com - Investing.com South Africa
Hims & Hers (HIMS) CMO logs RSU vesting and tax share withholding - Stock Titan
Hims & Hers (NYSE: HIMS) CFO exercises RSUs as shares withheld for tax - Stock Titan
Hims & Hers (HIMS) exec nets shares after 32,919 RSU conversion - Stock Titan
Hims & Hers (NYSE: HIMS) COO sells 14,027 shares, holds 432,124 - Stock Titan
Hims & Hers (NYSE: HIMS) PAO trades shares under 10b5-1 plan - Stock Titan
[Form 4] Hims & Hers Health, Inc. Insider Trading Activity - Stock Titan
Hims & Hers (NYSE: HIMS) CEO exercises RSUs and withholds shares for taxes - Stock Titan
Hims & Hers Health (HIMS) CTO exercises awards and sells 30,040 shares - Stock Titan
Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note - Yahoo Finance Singapore
Hims & Hers Health (HIMS) up 15.8% since last earnings report: Can it continue? - MSN
HIMS Stock Gained Nearly 6% On Wednesday — Barclays Sees Breakout Potential After Novo Partnership - Stocktwits
Hims & Hers Health Options Spot-On: On June 17th, 198.05K Contracts Were Traded, With 1.1 Million Open Interest - Moomoo
Hims Holdings (HIMS) Form 144: Director lists proposed sale of Class A shares - Stock Titan
[144] Hims & Hers Health, Inc. SEC Filing - Stock Titan
HIMS (NYSE) Form 144 shows insiders propose selling 14,027 and 97,289 Class A shares - Stock Titan
HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst - Yahoo Finance
Hims & Hers Enters A New Phase (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health Inc (HIMS) Stock Up 4.3% and Still Undervalued -- GF Score: 81/100 - GuruFocus
Hims & Hers Health Options Spot-On: On June 16th, 184.32K Contracts Were Traded, With 1.08 Million Open Interest - Moomoo
Hims & Hers Stands to Get a Big Chunk of the $2.2B Peptides Market - Barron's
Hims & Hers Stock Is Climbing Tuesday: What Investors Need To Know - Benzinga
Insider sells 5,529 Class A shares at HIMS (HIMS) via Fidelity - Stock Titan
Leerink reiterates Hims & Hers stock rating ahead of peptide meeting - Investing.com
3 Market-Beating Stocks with Exciting Potential - The Globe and Mail
Hims & Hers (HIMS) Climbs 12.5% as Obesity Market Momentum Builds - Insider Monkey
Hims & Hers Shareholders Reaffirm Board, Pay, and Auditor - TipRanks
Why Hims & Hers Health (HIMS) Is Up 11.0% After GLP-1 Weight Loss Pivot And Telehealth Deal - Yahoo Finance
Hims & Hers (NYSE: HIMS) director acquires 4,613 shares via RSU grants - Stock Titan
Hims & Hers (NYSE: HIMS) director converts 3,656 RSUs into common shares - Stock Titan
Hims & Hers Health (HIMS) director exercises 3,656 RSUs into common stock - Stock Titan
Hims & Hers (NYSE: HIMS) CMO exercises 4,091 RSUs, holds 187,971 shares - Stock Titan
Executive at Hims & Hers (HIMS) receives 3,656 shares from RSU vesting - Stock Titan
Hims & Hers (NYSE: HIMS) director Amoo-Gottfried Kofi Owusu files initial Form 3 - Stock Titan
Hims & Hers (NYSE: HIMS) director exercises RSUs for 14,343 shares - Stock Titan
Hims & Hers (HIMS) director gains 3,656 shares via RSU exercise - Stock Titan
Director at Hims & Hers (NYSE: HIMS) gains 13,696 shares through RSU exercises - Stock Titan
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):